Mena

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mena

Quick Facts

Property Description
Active ingredient Mometasone Furoate
Form Cream, Ointment, Lotion, Nasal Spray, Dry Powder Inhaler (DPI)
Pharmacological class Corticosteroid (Glucocorticoid)
Common use (General) Reduction of inflammation and allergic symptoms
Origin Synthetic steroid ester

What Type of Medicine is Mena?

Mena is a potent, prescription-only synthetic medicine whose active substance is Mometasone Furoate. This compound is a corticosteroid hormone receptor agonist and a potent glucocorticoid. Mometasone Furoate is synthesized as a steroid ester derivative. The distinct chemical structure of Mometasone Furoate is clinically recognized for delivering high localized activity with lower systemic exposure risk compared to older agents, and it is used as a single-ingredient product for targeted anti-inflammatory control.

What Forms Does Mometasone Furoate Come In?

Mometasone Furoate is prepared in various pharmaceutical forms, allowing for highly specific delivery based on the condition being addressed. These preparations include cream, ointment, lotion, or solution for topical application to the skin. Additionally, Mometasone Furoate is formulated as a nasal spray for the intranasal route and may be included in dry powder inhaler (DPI) formulations for the inhalation route. This diverse availability ensures the medicine can be administered directly to the target tissue, whether dermal, respiratory, or mucosal.

What is the General Purpose of Mena?

The general purpose of this medicine is to provide effective, high-level control over underlying inflammation and allergy. As a potent glucocorticoid, its key mechanism is to suppress the release and production of the body's natural chemical messengers that trigger inflammatory and allergic symptoms. Mometasone Furoate provides strong anti-inflammatory and anti-allergic effects in both dermal and respiratory applications. This medicine’s overall function is to stabilize the tissue response, thereby alleviating symptoms through fundamental biological control of the irritant response.

What side effects are possible with Mena?

Possible Side Effects and Safety Information

Mena (Mometasone Furoate) is a potent corticosteroid, and its safety profile is characterized by both local effects at the site of application and the potential for systemic absorption, a safety concern common to all glucocorticoids. All listed adverse reactions and safety statements are derived from official regulatory documentation.


General Safety Characteristics and Systemic Risk

Systemic absorption may lead to a clinically significant effect known as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, a potentially reversible condition that can cause glucocorticosteroid insufficiency, particularly upon treatment withdrawal. Other documented manifestations of systemic absorption include features of Cushing’s syndrome and hyperglycemia. The risk of systemic adverse reactions, including the development of glaucoma and/or cataracts, generally increases with prolonged use, especially when applied to large surface areas.


Safety Profile by Administration Route

Adverse reactions vary based on the pharmaceutical route:

Route Common Adverse Reactions (Examples) Serious Adverse Reactions (Examples)
Topical (Cream/Ointment) Burning, pruritus (itching), skin atrophy HPA axis suppression, Glaucoma/Cataracts
Nasal (Spray) Epistaxis (nosebleeds), pharyngitis, headache Nasal septum perforation, Local Candida infection
Inhaled (DPI) Headache, nasopharyngitis, pharyngitis Paradoxical bronchospasm, Local Candida infection

Population-Specific Safety Notes

The regulatory label notes specific constraints for certain groups. Pediatric patients may be more susceptible to systemic toxicity, and the use of nasal and inhaled forms is associated with a potential reduction in growth velocity. Furthermore, Mometasone Furoate is contraindicated in patients with known hypersensitivity and should be used cautiously in individuals with untreated local or systemic fungal, bacterial, viral, or parasitic infections, as corticosteroids can mask symptoms or worsen existing conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Mometasone Furoate (Mena) is primarily defined by the systemic effects that result from excessive or prolonged exposure to the corticosteroid. The principal documented physiological risk associated with high-dose or long-term misuse is Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This serious outcome can lead to hypercorticism, presenting with features similar to Cushing's syndrome, and may also result in documented metabolic findings such as hyperglycemia and glucosuria.


Management and Monitoring

If systemic effects or HPA axis suppression are identified, regulatory guidelines mandate supportive management. This includes the gradual withdrawal of the drug or a reduction in application frequency. For cases resulting in glucocorticosteroid insufficiency, supplemental systemic corticosteroids may be required. Periodic evaluation for HPA axis suppression is necessary, often involving the ACTH stimulation test. It is officially noted that pediatric patients are more susceptible to systemic toxicity due to their body composition.


When Immediate Medical Help is Required

In any situation classified as an acute overdose or accidental ingestion, the required emergency action is to seek immediate medical help or contact a Poison Control Center right away, as mandated by official regulatory documents detailing when urgent attention must be sought. No specific antidote is documented for Mometasone Furoate.

Therapeutic Uses of Mena

What Mena Treats: Main Uses and Benefits

Mena (Mometasone Furoate) may be part of symptomatic management in conditions where symptoms are related to inflammatory or irritative states. This use is applied across domains where additional symptomatic support is needed, with a focus on chronic manifestations.

This medicine is commonly used across conditions presenting with episodic or fluctuating symptom patterns, including eczema (atopic dermatitis), plaque psoriasis, seasonal and perennial allergic rhinitis, and may be part of symptomatic management for persistent asthma and nasal polyps. This supportive relief may assist with maintaining functional stability and supports patients during episodes of heightened discomfort.


Quick Fact: Symptom Management Context

Mena is considered relevant for managing symptoms linked to inflammatory or irritative processes, such as redness, scaling, and persistent itchiness (pruritus) in the skin, and nasal congestion, runny nose, and sneezing in allergic contexts. It offers support in contexts involving heightened systemic burden across the skin and respiratory system.

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Who can and cannot use Mena?

Eligibility for Mometasone Furoate (Mena) is strictly defined by official regulatory documentation, focusing on absolute prohibitions, age restrictions, and conditional use populations. Use is contraindicated in patients with documented hypersensitivity to the medicine or any of its formulation components. For topical applications, use is also restricted in populations with specific primary skin conditions, including facial rosacea, acne vulgaris, and untreated local infections.

Eligibility is highly dependent on age and the route of administration. Use of the topical cream and the nasal spray (for allergic rhinitis) is officially established in children 2 years of age and older. However, for specific indications like nasal polyps, eligibility is restricted to patients 18 years of age and older. Use is officially not established below these formulation-specific minimum age thresholds.

Special restrictions apply to certain physiological states and conditions. The medicine is classified for conditional use during pregnancy, meaning use is only permitted if the potential benefit justifies the potential risk, due to a lack of adequate human studies. Additionally, use requires caution in individuals with existing ocular conditions (such as glaucoma or cataracts) and must be avoided following recent nasal trauma or surgery until healing is complete.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The substance Mena refers to Menaquinone (Vitamin K2), which plays a direct role in the body’s blood clotting process. Therefore, its most significant and clinically relevant interaction is with Anticoagulants.


Anticoagulants

The primary concern is the interaction between Menaquinone and Vitamin K antagonists (VKAs), such as warfarin. VKAs work by inhibiting the recycling of Vitamin K, which reduces the synthesis of clotting factors. Since Menaquinone is a form of Vitamin K, its use can directly counteract the effect of warfarin, potentially making the anticoagulant less effective and increasing the risk of blood clots. Patients taking anticoagulants like warfarin must maintain a consistent and steady intake of Vitamin K through diet and supplements to ensure their blood coagulation levels (measured by INR) remain stable and within the therapeutic range. Fluctuations in Menaquinone intake can significantly destabilize anticoagulation control.


Other potential interactions

  • Certain Fat-Absorption Inhibitors: Medicines that inhibit the absorption of dietary fats, such as orlistat, may potentially decrease the absorption of Menaquinone, which is a fat-soluble vitamin. This pharmacokinetic effect could reduce the availability of Menaquinone in the body.
  • Broad-Spectrum Antibiotics: Extended use of certain broad-spectrum antibiotics may disrupt the gut flora that naturally produces some menaquinones, potentially altering the body’s endogenous supply of Vitamin K2. Patients should consult a healthcare provider regarding all concurrent medications and supplements to manage these potential interactions effectively.

Mechanism of Action

Mena's action is fundamentally described by its engagement with the GABA-A receptor complex. Specifically, Mena functions as a positive allosteric modulator of the receptor, interacting with binding sites distinct from those occupied by the primary endogenous ligand, gamma-aminobutyric acid (GABA). This interaction induces a conformational change in the receptor protein.

The resulting modification of the GABA-A receptor enhances the binding affinity of GABA and, crucially, increases the frequency of the associated chloride ion channel opening.

This heightened frequency allows a greater influx of negatively charged chloride ions (Cl^-) across the neuronal cell membrane, leading to hyperpolarization of the post-synaptic neuron.

At the intracellular level, this increase in transmembrane chloride flux raises the inhibition threshold and decreases the excitability of central nervous system (CNS) neurons. The downstream cascade results in a system-level modulation of neuronal activity, primarily manifest as a generalized reduction in CNS functional signaling. This physiological consequence is a direct outcome of the drug's specific molecular interaction with the inhibitory GABAergic system.

Dosage and Administration Information

Administration Guidelines

Administration of Mometasone Furoate (Mena) is highly dependent on the pharmaceutical form and its intended site of action. The medicine is administered via the Intranasal Route (as a metered-dose spray), the Topical Route (as a cream, ointment, or lotion), and the Oral Inhalation route.

The standard frequency for most initial and maintenance regimens, including allergic rhinitis and dermatoses, is once daily (QD). An increase to twice daily (BID) is used for specific conditions, such as the treatment of nasal polyps, if the initial once-daily dose is insufficient after a specified assessment period.

Preparation and Procedural Constraints

Specific preparation steps ensure dose consistency. The nasal spray bottle must be shaken well before each use and requires initial priming (e.g., 10 actuations) and subsequent repriming after seven days of non-use. For topical forms, a thin film is applied once daily, with the procedural constraint that the treated area must not be covered with an occlusive dressing unless directed.

Population and Missed Dose Rules

There are specific age-related considerations for use. For children aged 2 to 11 years, the intranasal dose is 100 mu g total once daily. For topical use in children aged 2 years and older, safety is not established for use longer than three weeks, and use is generally not established for infants under 2 years for either form. If a dose is missed, it should be taken as soon as remembered, but must not be doubled to make up for the missed timing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mena

Evidence for Use in Atopic Dermatitis (Eczema)

The research exploring Mena for atopic dermatitis involves numerous short-term Randomized Controlled Trials (RCTs) and comparative studies. These trials were primarily used in research exploring how symptoms change over time, and they focused on populations including adults and children, ranging from infants upward. Studies examined outcomes related to physical discomfort, specifically by measuring changes in disease severity scales like the SCORAD index, and by monitoring signs such as scaling, redness (erythema), and itchiness (pruritus).

Studies report on the course of measured symptom scores over defined time intervals, usually during the initial two to four weeks of use. Regulatory reviews noted that the evidence describes findings focused on short-term symptom patterns in this condition. A key limitation is that follow-up durations were limited in many trials. While research provides insight into short-term changes, there is limited information for long-term outcomes regarding the sustained stability of the skin or the prevention of symptom flare-ups over many months.

Evidence for Use in Allergic Rhinitis

For seasonal and perennial allergic rhinitis, research explored the intranasal spray formulation in many double-blind, placebo-controlled RCTs. Research examined outcomes measured by the Total Nasal Symptom Score (TNSS), which is used in studies examining symptom intensity or variability of issues like nasal congestion, runny nose, and sneezing. The populations evaluated were primarily adults and adolescents, but the research also included children as young as two years of age.

Research highlights the recorded measurements during the study period, which provided data on symptom score movement in trials conducted during periods of increased symptom activity. While short-term evidence is widely available, the long-term effects are not fully established beyond several months of continuous use for perennial allergic rhinitis. Research provides context but not individual predictions.

What is Still Uncertain about Mena: Research Gaps

Research has identified several aspects that require further study. There is limited information for long-term outcomes regarding the continuous use of the medicine for chronic conditions such as eczema and rhinitis, and the durability of response after stopping treatment. Furthermore, results apply only to the populations studied, and comparative evidence examining Mena against every alternative therapy is lacking or varies across studies. The evidence quality varies across studies, and some subgroup findings are uncertain.

Key Studies & References

  1. MOMETASONE FUROATE cream, for topical use (DailyMed - NIH)
  2. Mometasone furoate nasal spray: a systematic review (MRM Journal)
  3. Frequency of application of topical corticosteroids for atopic eczema - NICE Guidance (Evidence and interpretation)

Frequently Asked Questions (FAQ)

Common questions about Mena (FAQ)


Q: What happens if you miss a dose of Mena?

A: If a dose is forgotten, official administration guidance suggests taking it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, it is advised to skip the missed dose and return to the regular schedule. Regulatory guidance warns that a double dose must not be taken to compensate for the one that was missed.


Q: Can you take Mena if you are also taking vitamins or herbal supplements?

A: Official product information advises that patients inform their healthcare provider about all concurrent medications, including prescription and over-the-counter medicines, vitamins, and any herbal supplements. This allows the provider to check for potential interactions and minimize the risk of altered drug effects or side effects.


Q: What interactions does Mena have with common pain relievers like ibuprofen?

A: Mena is a corticosteroid, and official warnings indicate that patients should fully disclose all medicines they are taking. Using multiple products containing corticosteroids can increase the risk of systemic side effects. A healthcare provider can confirm if specific pain relievers are appropriate to use alongside this medication.


Q: Does Mena interact with common antidepressants?

A: Regulatory warnings state that patients must discuss all medications, including antidepressants, with their healthcare provider. Certain drugs, such as strong CYP3A4 inhibitors (a group that includes some antidepressants), may slow the breakdown of Mena in the body. This can potentially lead to higher systemic levels of the medicine and increase the risk of related side effects.


Q: Is it possible to be allergic to Mena?

A: Yes, regulatory information states that Mena is contraindicated (should not be used) if a person has a known hypersensitivity or allergy to the drug or any of its ingredients. Any signs of a suspected allergic reaction should be promptly reported to a healthcare professional for evaluation.


Q: What are the signs that I should contact a doctor about a side effect from Mena?

A: Patients are advised to contact a healthcare provider if signs of certain systemic side effects are noticed, such as changes in vision (like blurred vision) or symptoms of infection (like fever or chills). They should also seek advice if they experience symptoms related to reduced adrenal gland function, such as unusual tiredness, persistent nausea, or weight loss.


Q: Does Mena affect fertility in men or women?

A: The regulatory label sections that review the drug's effects do not consistently provide a definitive statement on the impact of Mena on human fertility for the general population. Concerns about fertility and the medicine should be discussed with a healthcare professional.


Q: What warnings should I look for on the Mena packaging?

A: Official warnings relate to the potential for systemic effects if too much medicine is absorbed into the body. These include the risk of conditions like Adrenal Suppression (a hormone imbalance) and ocular conditions like Glaucoma or Cataracts. Additionally, the risk of local infections should be considered, particularly with prolonged use.


Q: Is Mena safe for people who drive or operate heavy machinery?

A: Reported adverse events from clinical trials have included headache and dizziness. Official guidance recommends that patients observe how they react to Mena before driving or operating heavy machinery to ensure they are not experiencing any side effects that could impair their abilities.


Q: What are the severe but rare side effects of Mena?

A: Severe, though less common, systemic side effects can occur due to the medicine being absorbed throughout the body. These include the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression (affecting hormone balance), and the risk of developing Glaucoma or Cataracts. For nasal spray, a rare local effect is nasal septum perforation.


Q: Is it normal to feel [Symptom X, e.g., slightly dizzy] when starting Mena?

A: Clinical trial data lists adverse events such as headache and dizziness as having been reported by some patients. Regulatory documents, however, do not specify whether the initial onset of these mild symptoms is 'normal' or expected for every user. Persistent symptoms should be communicated to a healthcare provider.


Q: Is it normal to have [Mild Symptom Y] after taking Mena for several months?

A: The risk of systemic side effects, particularly serious ones like Glaucoma or Cataracts, increases with prolonged use. New or persistent mild symptoms experienced after several months of use should be discussed with a healthcare provider for evaluation to ensure continued safe use.


Q: Can people with a history of liver problems take Mena?

A: Official information indicates that use should be done with caution in patients with hepatic impairment (liver disease). This caution is necessary because the presence of liver disease may slow the removal of the drug from the body, potentially increasing its effects.


Q: Is Mena safe for older adults to use?

A: Official data indicates that certain clinical trials included patients 65 years and older without identifying differences in effectiveness or safety compared to younger adults. However, caution is advised because older adults more frequently experience reduced function in organs like the kidneys, liver, or heart.


Q: Can people with kidney issues take Mena?

A: The regulatory label does not consistently detail specific dosage adjustments solely for kidney impairment across all formulations. However, because reduced kidney function is more common in older adults, caution is generally warranted when prescribing Mena to this population.


Q: How quickly does Mena start working after you take it?

A: For the nasal spray formulation used to treat allergic rhinitis, a clinically significant onset of action has been noted within 12 hours for some patients. The full or median time to symptom relief is typically noted to be around 36 hours in clinical trials.


Q: Does Mena cause weight gain?

A: Weight gain, particularly changes in body fat distribution like increased upper body and facial weight, can be a symptom of a rare, serious systemic side effect called Cushing's syndrome. This occurs if too much corticosteroid is absorbed into the bloodstream over a long period.


Q: Will taking Mena make me feel drowsy or tired?

A: Unusual tiredness or weakness is listed as a potential symptom of systemic adverse effects, specifically the reduction of adrenal gland function. If this symptom is noticed, prompt reporting to a healthcare provider is recommended.


Q: How long does Mena stay in your system?

A: For inhaled doses, the time it takes for half of the medicine to be cleared from the system is approximately 5 to 5.8 hours. Systemic absorption (how much gets into the bloodstream) is generally very low—less than 1%—for nasal and topical forms.


Q: Can Mena be split or crushed, or does it have to be swallowed whole?

A: Mena is formulated as a nasal spray, topical cream/ointment, or dry powder inhaler, which are not designed to be manipulated. Administration must strictly follow the directions for that specific dosage form, such as shaking the spray bottle or applying a thin film to the skin.


Q: Does Mena affect sleep patterns?

A: Sleep problems, such as insomnia, have been noted as potential symptoms associated with systemic side effects, particularly if the medicine is absorbed at high levels over time, such as in the case of Cushing’s syndrome.


Q: Is there a maximum time someone can safely be on Mena?

A: For the topical use in children (2 years and older), safety has not been established for use longer than three weeks. For other indications, treatment should generally be stopped when control of the underlying condition has been successfully achieved.


Q: What is the expected timeline for seeing the full effect of Mena?

A: The official product information indicates that for topical skin conditions, the diagnosis should be reassessed if no improvement is seen within 2 weeks. For the nasal spray, while initial relief is faster, the full therapeutic benefit may take several days or up to two weeks of continuous use.


Q: Are there any withdrawal symptoms when stopping Mena?

A: Abruptly stopping the medicine, especially after prolonged use, carries a risk of developing glucocorticosteroid insufficiency, which is related to the suppression of the adrenal gland. This condition can cause symptoms such as weakness, fatigue, and low blood pressure.


Q: Do you have to take Mena at the exact same time every day?

A: Mena is typically prescribed as a once-daily dose for most indications. Taking the medicine consistently around the same time each day helps maintain stable levels of the drug in the body, which is important for controlling chronic conditions like allergic rhinitis.


Q: Does Mena affect blood pressure readings?

A: While not a common side effect, systemic absorption of corticosteroids can potentially lead to changes in blood pressure. Low blood pressure can be a sign of adrenal insufficiency, and high blood pressure can also be a rare symptom of Cushing's syndrome.


Q: Does Mena cause changes in mood or anxiety?

A: Changes in mood, including reports of depressed mood or anxiety, are listed as potential symptoms associated with systemic adverse effects, such as Cushing’s syndrome. This risk is tied to the long-term, high-level absorption of the corticosteroid.

How should Mena be stored and disposed of?

Storage and Disposal Conditions for Mometasone Furoate

Mometasone Furoate products must be stored at controlled room temperature, maintaining 20 C to 25 C (68 F to 77 F). The medicine must be protected from direct light, heat, and moisture, and must not be frozen.

All formulations should be stored in a closed container and kept out of the sight and reach of children.

For the nasal spray, the device must be re-primed if unused for over one week and must be discarded after the labeled dose count (e.g., 120 sprays). Unused or expired product should not be kept and must be disposed of safely according to local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mena found in:

A-Z Index: